Article
Refine
Year of publication
- 2019 (500) (remove)
Document Type
- Article (500) (remove)
Has Fulltext
- yes (500)
Is part of the Bibliography
- no (500)
Keywords
- inflammation (10)
- glioblastoma (8)
- cancer (7)
- Breast cancer (6)
- biomarker (6)
- Inflammation (5)
- breast cancer (5)
- immunotherapy (5)
- mTOR (5)
- Biomarkers (4)
- Chemotherapy (4)
- Gene expression (4)
- Human behaviour (4)
- Oncology (4)
- autophagy (4)
- cirrhosis (4)
- fMRI (4)
- glioma (4)
- hypoxia (4)
- infection (4)
- invasion (4)
- macrophage (4)
- microRNA (4)
- mitochondria (4)
- Aortic valve (3)
- Cancer treatment (3)
- Children (3)
- Cirrhosis (3)
- Death rates (3)
- Depression (3)
- Drug therapy (3)
- Germany (3)
- HDAC (3)
- Hemorrhage (3)
- Immunotherapy (3)
- Mental health and psychiatry (3)
- Molecular neuroscience (3)
- Multivariate analysis (3)
- Neutropenia (3)
- Outcome (3)
- Predictive markers (3)
- Prognosis (3)
- Prävention (3)
- Quality of life (3)
- Research article (3)
- T cells (3)
- acute coronary syndrome (3)
- angiogenesis (3)
- complications (3)
- cytokines (3)
- differentiation (3)
- efficacy (3)
- epilepsy (3)
- integrin (3)
- leukemia (3)
- macrophage polarization (3)
- macrophages (3)
- monocytes (3)
- mycophenolic acid (3)
- neoadjuvant therapy (3)
- p21 (3)
- peripheral artery disease (3)
- prevention (3)
- reactive oxygen species (3)
- risk factors (3)
- sepsis (3)
- surgery (3)
- tumor microenvironment (3)
- vitamin D (3)
- Acute inflammation (2)
- Acute myeloid leukemia (2)
- Adverse events (2)
- Age groups (2)
- Alpelisib (2)
- Apoptosis (2)
- Aspergillus fumigatus (2)
- Atezolizumab (2)
- B cells (2)
- Biomarker (2)
- Body mass index (2)
- CAD/CAM (2)
- CC16 (2)
- CDKN1A (2)
- CIK cells (2)
- Cancer (2)
- Cancer chemotherapy (2)
- Cancer genomics (2)
- Cardiac hypertrophy (2)
- Cell differentiation (2)
- Cell proliferation (2)
- Clinical presentation (2)
- Cognition (2)
- Crohn’s disease (2)
- Cytokines (2)
- DMEK (2)
- DNA methylation (2)
- Developmental biology (2)
- Diagnostic medicine (2)
- Digestive system procedures (2)
- EGFR (2)
- Ears (2)
- Ejection fraction (2)
- Endothelial cells (2)
- Epidemiology (2)
- Fatty liver (2)
- HBV (2)
- HSV (2)
- Heart (2)
- Heart failure (2)
- Hepatitis C virus (2)
- Hospitals (2)
- Hypertension (2)
- IBD (2)
- Incidence (2)
- Infectious diseases (2)
- Inflammatory diseases (2)
- Ischemia (2)
- Katherine (2)
- Knowledge (2)
- Liver diseases (2)
- MYC (2)
- Machine learning (2)
- Macrophages (2)
- Magnetic resonance imaging (2)
- Mammakarzinom (2)
- Mesenchymal stem cells (2)
- Messenger RNA (2)
- Metastasen (2)
- Molecular medicine (2)
- Mouse (2)
- NADPH oxidase (2)
- Obesity (2)
- Ophthalmology (2)
- Outcomes (2)
- PARP (2)
- PD-L1 (2)
- PD‑L1 (2)
- PI3K (2)
- Patients (2)
- Pediatric infections (2)
- Personalized medicine (2)
- Pregnancy (2)
- Psychiatric disorders (2)
- RITA (2)
- Radiomics (2)
- Sepsis (2)
- Sleep (2)
- Stroke (2)
- Suicide (2)
- Supportivtherapie (2)
- Surgery (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Transcription factors (2)
- Treatment (2)
- T‑DM1 (2)
- additives (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- aged (2)
- alirocumab (2)
- alpelisib (2)
- antiviral therapy (2)
- apoptosis (2)
- arteriogenesis (2)
- astrocytes (2)
- atezolizumab (2)
- attention (2)
- bone metabolism (2)
- brain metastases (2)
- caspase-2 (2)
- cholesterol (2)
- chronic kidney disease (2)
- classical Hodgkin lymphoma (2)
- cognition (2)
- colorectal cancer (2)
- complement (2)
- corneal edema (2)
- corneal transplantation (2)
- curcumin (2)
- cyclosporin A (2)
- cytomegalovirus (2)
- data science (2)
- dementia (2)
- dental implant (2)
- early breast cancer (2)
- echocardiography (2)
- eicosanoids (2)
- electrolytic cleaning (2)
- environmental tobacco smoke (2)
- extracellular matrix (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- graph theory (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- human (2)
- immune evasion (2)
- innate immunity (2)
- integrins (2)
- liver disease (2)
- lncRNA (2)
- magnetic resonance imaging (2)
- metabolic syndrome (2)
- metastatic (2)
- methylprednisolone (2)
- migration (2)
- modularity (2)
- mortality (2)
- multiple sclerosis (2)
- music (2)
- neoadjuvante Therapie (2)
- obesity (2)
- osteoporosis (2)
- particulate matter (2)
- periimplantitis (2)
- pharmacovigilance (2)
- phosphorylation (2)
- portal hypertension (2)
- primary care (2)
- primary health care (2)
- proliferation (2)
- prostaglandins (2)
- prostate cancer (2)
- proteome (2)
- proteomics (2)
- psoriasis (2)
- quantitative MRI (2)
- radical prostatectomy (2)
- radiotherapy (2)
- registry (2)
- renal function (2)
- secretome (2)
- signal transduction (2)
- sphingosine-1-phosphate (2)
- supportive therapy (2)
- targeted therapy (2)
- transplantation (2)
- trauma (2)
- tumor-associated macrophages (2)
- uteroglobin (2)
- (novel) brominated flame retardants ((N)BFR) (1)
- (surface) partial differential equations (1)
- 15-PGDH (1)
- 3Cs technology (1)
- 3D spatiotemporal resolved mathematical models (1)
- 3D tissue models (1)
- 3years (1)
- 5' UTR (1)
- 6-Schritt-Methode (1)
- A375 human melanoma cell line (1)
- AB-serum (1)
- ACL (1)
- ACLF (1)
- AICAR (1)
- AIS (1)
- ALF (1)
- AMD3100 (1)
- AML (1)
- AMPK (1)
- APRI (1)
- ASCT (1)
- AT-101 (1)
- ATG4 (1)
- ATG8 (1)
- ATM (1)
- ATO (1)
- AVM hemorrhage (1)
- Abdominal surgery (1)
- Abdominal trauma (1)
- Abiraterone acetate (1)
- Actinomycin D (1)
- Action potential (1)
- Addison’s disease (1)
- Adenocarcinoma (1)
- Adhesins (1)
- Adhesion (1)
- Adipose-derived mesenchymal stem cells (1)
- Adjustment of dosage at steady state (1)
- Adolescents (1)
- Agoraphobia (1)
- Akutes Koronarsyndrom (1)
- Alleles (1)
- Allergen immunotherapy (1)
- Allergoid (1)
- Aminotransferases (1)
- Anemia (1)
- Anesthesia, Intravenous (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Aneurysms (1)
- Angiogenesis (1)
- Angiography (1)
- Anosmia (1)
- Antibody isotypes (1)
- Anticoagulants [MeSH] (1)
- Anticoagulation (1)
- Antigen-presenting cells (1)
- Antigens (1)
- Antiplatelet therapy (1)
- Antireflux surgery (1)
- Antiviral therapy (1)
- Anura (1)
- Aortic aneurysm (1)
- Aortic arch replacement (1)
- Aortic dissection (1)
- Aortic stenosis (1)
- Aortic stiffness (1)
- Aortic valve replacement (1)
- Aortic valve sparing (1)
- Apes (1)
- Arabin pessary (1)
- Arabin-Pessar (1)
- ArchT (1)
- Aromatase Inhibitors (1)
- Arrhythmia (1)
- Artificial intelligence (1)
- Aspergillus species (1)
- Asphyxia (1)
- Ataxia telangiectasia (1)
- Atelopus carbonerensis (1)
- Atelopus mucubajiensis (1)
- Atelopus tamaense (1)
- Atrial fibrillation (1)
- Attention (1)
- Attitude (1)
- Audio equipment (1)
- Audio signal processing (1)
- Audiology (1)
- Aurora A (1)
- Aurora Ax (1)
- Australia (1)
- Austria (1)
- Automated sRNA analysis (1)
- Autophagy (1)
- Awareness (1)
- Axon (1)
- B cell malignancies (1)
- B cell precursor acute lymphoblastic leukemia (1)
- B-cell antigen receptor (1)
- BBB (1)
- BCL2 (1)
- BI1361849 (1)
- BIAM switch assay (1)
- BMAC (1)
- BNC2 (1)
- BRAF mutation (1)
- Back pain (1)
- Bartonella (1)
- Biliary tree (1)
- Bilirubin (1)
- Biomarkers & Diagnostic Imaging (1)
- Biotechnology (1)
- Bipolar disorder (1)
- Blood (1)
- Blood groups (1)
- Blood plasma (1)
- Blood pressure (1)
- Blood-brain barrier (1)
- BluePrint (1)
- Body-contouring surgery (1)
- Bone marrow (1)
- Bone marrow aspirate concentrate (1)
- Bone marrow aspiration (1)
- Bone strength assessment (1)
- Borrelia (1)
- Brain metastasis (1)
- Breast neoplasms (1)
- Breast tumors (1)
- Bufonidae (1)
- Burst (1)
- C-reactive protein (1)
- C-reactive proteins (1)
- C1 esterase inhibitor (human) (1)
- C1-esterase inhibitor protein (1)
- C3M (1)
- C4M (1)
- CAM (1)
- CD271 (1)
- CD3/CD19 depletion (1)
- CD36 (1)
- CD45RA naïve lymphocytes (1)
- CD8+ T lymphocytes (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CHA2DS2-VASc-score (1)
- CHIP (1)
- CLP (1)
- CREB inhibitor (1)
- CRISPR/Cas (1)
- CRM (1)
- CRT-D (1)
- CTLA-4 (1)
- CV9202 (1)
- CVD biomarker (1)
- CVID (1)
- CWS Studiengruppe (1)
- CXCL12 (1)
- Caco-2 cells (1)
- Canada (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer therapeutic resistance (1)
- Cannabis (1)
- Carcinoma, Ductal, Breast (1)
- Cardiac device therapy (1)
- Cardiac monitoring (1)
- Cardiac necroenzymes (1)
- Cardiac remodelling (1)
- Cardiology (1)
- Cardiovascular Magnetic Resonance (CMR) (1)
- Cardiovascular epidemiology (1)
- Case management [MeSH] (1)
- Cell binding (1)
- Cell biology (1)
- Cell motility (1)
- Cell therapy (1)
- Cellular stress responses (1)
- Center-specific time in therapeutic range (cTTR) (1)
- Central nervous system metastases (1)
- Cerebral toxoplasmosis HIV (1)
- Cerebral vasospasm (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical company (1)
- Chemosensitivity (1)
- Chlorides (1)
- Cholesterin (1)
- Chromatin accessibility (1)
- Chronic disease [MeSH] (1)
- Chronic health condition (1)
- Chronic hepatitis (1)
- Chronic hepatitis C virus (1)
- Chronic kidney disease (1)
- Chronic obstructive pulmonary disease (1)
- Citation analysis (1)
- Clincial pharmacology (1)
- Clinical effectiveness (1)
- Clinical pathways (1)
- Clinical studies (1)
- Clinical trial (1)
- Clostridioides difficile (1)
- Cognitive impairment (1)
- Cognitive neuroscience (1)
- Cognitive psychology (1)
- Colchicum (1)
- Collagen (1)
- Collagens (1)
- Colloids (1)
- Colorectal cancer (1)
- Combined immune checkpoint blockade (1)
- Community based intervention (1)
- Community health services (1)
- Comparative analysis (1)
- Complement cascade (1)
- Complication management (1)
- Comprehensive cancer centers (1)
- Computational biology and bioinformatics (1)
- Computational model (1)
- Computational sRNA analysis (1)
- Conduct disorder (1)
- Congenital duodenal obstruction (1)
- Contrast-enhanced (1)
- Cornea (1)
- Coronary heart disease (1)
- Cost-effectiveness (1)
- Cost-effectiveness analysis (1)
- Costs (1)
- Crispr/Cas (1)
- Cross-frequency coupling (1)
- Cross-sectional study (1)
- Cumulative dose (1)
- Cure (1)
- Curvilinear dose response (1)
- Cytochrome P450 enzymes (1)
- Cytogenetics (1)
- Cytoplasm (1)
- Cytoplasmic staining (1)
- Cytoskeletal proteins (1)
- Cytoskeleton (1)
- C‐reactive protein (1)
- DDA (1)
- DDIT4 (1)
- DHA (1)
- DILI (1)
- DME (1)
- DNA damage (1)
- DNA damage response (1)
- DNA repair (1)
- DNA-binding proteins (1)
- DNase1-seq (1)
- DSAEK (1)
- DUBs (1)
- Data mining (1)
- Data processing (1)
- Data science (1)
- David technique (1)
- Decision (1)
- Decision impact (1)
- Decision trees (1)
- Delayed union (1)
- Deletion mutation (1)
- Dental education (1)
- Dental students (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Diagnostic test (1)
- Direct Acting Antivirals (DAA) (1)
- Direct acting antiviral therapies (1)
- Disabling back pain (1)
- Disease burden (1)
- Docetaxel (1)
- Dog (1)
- Dopamine (1)
- Dorsolateral prefrontal cortex (1)
- Doxorubicin (1)
- Dual energy CT (1)
- Duodenal atresia (1)
- Duodenal stenosis (1)
- E protein structure (1)
- EEG (1)
- EGFP (1)
- EGFR inhibitor (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- EPA (1)
- ERK3/MAPK6 (1)
- ERM (1)
- ERP (1)
- Economic analysis (1)
- Economics (1)
- Edentulous jaw (1)
- Education (1)
- Eicosanoids (1)
- Einreibetechnik (1)
- Electrical accident (1)
- Electrical stimulation (1)
- Electroencephalography – EEG (1)
- Electrolytes (1)
- Electrophysiology (1)
- Emergency (1)
- Emotion processing (1)
- Emotion regulation (1)
- Emotions (1)
- Empfehlungen (1)
- Employment (1)
- EndMT (1)
- Endoscopy (1)
- Ensemble learning (1)
- Enterobacteriaceae (1)
- Entfernung (1)
- Enzyme regulation (1)
- Enzyme-linked immunoassays (1)
- Epilepsy (1)
- Erythropoiesis (1)
- Esophageal adenocarcinoma (1)
- Esophageal adenocarcinoma (EAC) (1)
- Esophagectomy (1)
- Estrogen Receptor Modulators (1)
- Eukaryotic sRNA (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Evaluation (1)
- Evaluationspraxis (1)
- Evidence based medicine (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced bronchoconstriction (1)
- Experimental models of disease (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extracellular matrix proteins (1)
- Extracellular signal-regulated kinase 1/2 (1)
- Eyes (1)
- FAK (1)
- FFLU (1)
- FFPE (1)
- FIB-4 (1)
- Fatty acids (1)
- FemNAT-CD (1)
- Female adolescents (1)
- Femoral neck (1)
- Fevers (1)
- Fibroblast growth factor (1)
- Fibronectin (1)
- Fibrosis (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Finite Volumes (1)
- First site of metastatic disease (1)
- Fistula (1)
- Flaps (1)
- Fluorescence-in-situ-hybridization (FISH) (1)
- Foramen ovale (1)
- Forkhead box (1)
- Fracture risk (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- Frühgeburt (1)
- Functional electrical stimulation (1)
- Functional magnetic resonance imaging (1)
- Functional outcome (1)
- Funding (1)
- FungiScope® registry (1)
- G-protein (1)
- G/P (1)
- GRK2 (1)
- Gait analysis (1)
- Galleria mellonella (1)
- Gastric cancer (1)
- Gastroesophageal reflux disease (1)
- Gastroesophageal reflux disease symptoms (1)
- Gaucher disease type III (1)
- Gaucher’s disease (1)
- Gender reassigning surgery (1)
- Gene prediction (1)
- Gene regulation (1)
- General practice (1)
- General practitioner (1)
- General practitioners (1)
- Generation Y (1)
- Genome annotation (1)
- Genomic instability (1)
- German PID-NET registry (1)
- German people (1)
- Gleason upgrading (1)
- Glioblastoma (1)
- Global health (1)
- Glomerular Filtration Rate (1)
- Glucose Transporter Type 1 (1)
- Glycogen synthase kinase 3 beta (1)
- Goserelin (1)
- Grafts (1)
- Gram-negative bacteria (1)
- Grass pollen (1)
- Growth factors (1)
- Guided surgery (1)
- HAEGARDA (1)
- HAI‐1 (1)
- HCV (1)
- HDACi (1)
- HER2/neu (ERBB2) (1)
- HGF (1)
- HIF1α (1)
- HIV (1)
- HNSCC (1)
- HOD (1)
- HODE (1)
- HPV (1)
- HSV-1 (1)
- HSV-2 (1)
- HUVEC (1)
- Haplotypes (1)
- Head and neck Cancer (1)
- Health care (1)
- Health economics (1)
- Health services research [MeSH] (1)
- Healthcare worker (1)
- Hedgehog (1)
- Hemoglobin (1)
- Hemophilia A (1)
- Hemorrhagic shock (1)
- HepG2 (1)
- HepaRG cells (1)
- Hepatitis B (1)
- Hepatitis B infection (1)
- Hepatitis B vaccination (1)
- Hepatitis C (1)
- Hepatocytes (1)
- Hereditary angioedema (1)
- High-risk patient (1)
- Hippo signaling (1)
- Hippocampus (1)
- Histology (1)
- Hodgkin lymphoma (1)
- Holmes tremor (1)
- Homeostasis (1)
- Homicide (1)
- Hospitalizations (1)
- Host-directed therapies (1)
- Huh7 (1)
- Human (1)
- Human genetics (1)
- Human olfaction (1)
- Humeral fractures (1)
- Humerus (1)
- Hungary (1)
- Hydrocephalus (1)
- Hyperammonemic encephalopathy (1)
- Hypofractionated radiotherapy (1)
- Hypoxic responses (1)
- I-FABP (1)
- ICU (1)
- IGF (1)
- IL-15 (1)
- IL-1β (1)
- IL-21 (1)
- IL-27 cytokine (1)
- IL-33 (1)
- IL10R (1)
- ILUVIEN (1)
- IPEX (1)
- IPS e.max system (1)
- ISS (1)
- IUIS classification 2017 (1)
- IgE (1)
- IgG substitution therapy (1)
- IgGAM (1)
- Illumina (1)
- Image analysis (1)
- Imaging genetics (1)
- Immediate loading (1)
- Immediate placement (1)
- Immune Response (1)
- Immune cells (1)
- Immunoassays (1)
- Immunogenicity (1)
- Immunohistochemistry (1)
- Immunohistochemistry techniques (1)
- Immunomonitoring (1)
- Immunostaining (1)
- Immunosuppressive Agents (1)
- Implant-supported bars (1)
- In-line filtration (1)
- IncL (1)
- Incidence rate (1)
- Independent laboratories (1)
- Indirect-binding (1)
- Individual differences (1)
- Infarction (1)
- Infusion management (1)
- Insulin resistance (1)
- Integrated multimodal training (1)
- Intelligence (1)
- Intelligence tests (1)
- Intensive care (1)
- Intensive care units (1)
- Interleukin-17A (1)
- Interleukin-18 (1)
- Interleukin-18 binding protein (1)
- Interleukin-22 (1)
- Interleukin-22 binding protein (1)
- Interventional Trials (1)
- Interventional cardiology (1)
- Intracranial embolism (1)
- Intraoral scanners (1)
- Invasive fungal infection (1)
- Invasive fungal infections (1)
- Ipilimumab (1)
- Ireland (1)
- Iron deficiency (1)
- Iron deficiency anemia (1)
- JAK inhibition (1)
- Joint loading (1)
- KIF (1)
- KIF11 (1)
- Karyotypes (1)
- Ketogenic Diet (1)
- L-DOPA (1)
- LAMTOR2 (1)
- LC-NE system (1)
- LC3 I/II (1)
- LC–MS/MS (1)
- LDL (1)
- LM11A 31 (1)
- LN229 (1)
- LPP (1)
- LRBA (1)
- LSCC (1)
- LSD1 (1)
- LUT (1)
- Labor and delivery (1)
- Laboratory techniques and procedures (1)
- Lafora disease (1)
- Laminin (1)
- Laparoscopic fundoplication (1)
- Late Gadolinium Enhancement (LGE) (1)
- Late presentation (1)
- Left hemisphere (1)
- Leg alignment (1)
- Legs (1)
- Leistungsorientierte Mittelvergabe (1)
- Lesion (1)
- Lesions (1)
- Liver (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Liver-Related Complications (1)
- Lomentospora prolificans (1)
- Long noncoding RNA (1)
- Long term output (1)
- Long-term (1)
- Luciferase (1)
- Lumbar spine (1)
- Lyme disease (1)
- Lymph nodes (1)
- Lymphadenopathy (1)
- Lymphangioleiomyomatosis (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- Lymphomas (1)
- Lysosomal storage disease (1)
- MAIT cell (1)
- MALAT1 (1)
- MEG (1)
- MMP2 (1)
- MRI patterns of gliomas (1)
- MRSA (1)
- Machine-learning (1)
- Magnetic resonance imaging (MRI) (1)
- Malaria prevalence (1)
- MammaPrint (1)
- Mammaplasty (1)
- Markov model (1)
- Masquelet technique (1)
- Mass spectrometry (1)
- Mastectomy (1)
- Maxillary sinus (1)
- Mechanisms of disease (1)
- Meckel’s diverticulum (1)
- Medical education (1)
- Medical research (1)
- Medicine and health sciences (1)
- Membrane potential (1)
- Mesenchymal stem cell (1)
- Mesenchymal stromal cells (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Metabolism, Inborn Errors (1)
- Metalloproteases (1)
- Metastasis (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic tumors (1)
- Methacholine challenge test (1)
- Methicillin-resistant Staphylococcus aureus (1)
- MiSpEx Network (1)
- MicroRNAs (1)
- Microbiome (1)
- Microphones (1)
- Molecular profiling (1)
- Molecular signatures (1)
- Molecular subtype (1)
- Molecular subtypes (1)
- Monosaccharide Transport Proteins (1)
- Monte Carlo simulation (1)
- Morbidity (1)
- Morphogenesis (1)
- Motor control (1)
- Mouse models (1)
- Mucopolysaccharidoses (1)
- Multi-nucleated cardiomyocytes (1)
- Multidrug-resistant tuberculosis (1)
- Multinomial logistic regression (1)
- Multivariable analysis (1)
- NASH (1)
- NCH93 (1)
- NDR1 (1)
- NDUFAF8 (1)
- NEAT1 (1)
- NEAT2 (1)
- NGS (1)
- NK cell (1)
- NK cells (1)
- NK-92 (1)
- NKG2D (1)
- NKT cell (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NMDAR subunit GluN2B (1)
- NOTCH1 (1)
- NPSR1 (1)
- NSAIDs (1)
- Nanopore (1)
- Native T1 (1)
- Native T1 mapping (1)
- Nav channel activity (1)
- Nav1.7 (1)
- Neonatal urea cycle disorders (1)
- Neonates (1)
- Network model (1)
- Neuro-ophthalmology (1)
- Neuroimaging (1)
- Neuroscience (1)
- Nivolumab (1)
- Non-REM sleep (1)
- Non-coding RNA (1)
- Non-invasive brain stimulation (1)
- Non-small cell lung cancer (1)
- Nonunion (1)
- Notch (1)
- Nox4 (1)
- Numerical simulation (1)
- OXA-48 (1)
- Occupational medicine (1)
- Olfactory diagnostics (1)
- One health (1)
- Opacity (1)
- Oposterior urethral valve (1)
- Opportunistic infections (1)
- Optical lenses (1)
- Oral Health Impact Profile (OHIP) (1)
- Oral and maxillofacial surgery (1)
- Oral anticoagulation (1)
- Oral implantology (1)
- Oral surgery (1)
- Organ dysfunction (1)
- Oroantral (1)
- Oroantral communication (1)
- Osteogenic differentiation (1)
- Osteoporosis diagnosis (1)
- PCP (1)
- PCSK9 protein (1)
- PEI (1)
- PF-06273340 (1)
- PGE2 (1)
- PID prevalence (1)
- PINK1 (1)
- PKCε (1)
- PLK1 inhibitors (1)
- PPARγ (1)
- Paediatric research (1)
- Pain (1)
- Pancreatic surgery (1)
- Pancreatoduodenectomy (1)
- Panic disorder (1)
- Parapneumonic pleural effusion (1)
- Parkinson disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathogenesis (1)
- Pathogenicity (1)
- Patient preferences (1)
- Pause (1)
- Pediatric patients (1)
- Pediatrics (1)
- Pentaglobin (1)
- Peritonitis (1)
- Personalised medicine (1)
- Pharm-fMRI (1)
- Pharmacometrics (1)
- Philadelphia chromosome-positive acute leukemia (1)
- Phylogenetic analysis (1)
- Platelet-rich fibrin (1)
- Platelets (1)
- Platzierung (1)
- Plerixafor (1)
- Pleural empyema (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Polyunsaturated fatty acids (1)
- Ponatinib (1)
- Portal veins (1)
- Portugal (1)
- Posaconazole serum level (1)
- Positron-emission tomography (1)
- Post treatment (1)
- Precision (1)
- Precision oncology (1)
- Prenatal ultrasonographic detection rate (1)
- Preoperative diagnostics (1)
- Prevalence (1)
- Prevention (1)
- Primary care (1)
- Primary cilium (1)
- Primary health care [MeSH] (1)
- Prisoners (1)
- Prisons (1)
- Profilometry (1)
- Prognostic biomarker (1)
- Prophylaxis (1)
- Prostaglandin (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Protease inhibitor therapy (1)
- Protein translation (1)
- Proteomics (1)
- Proteostasis (1)
- Proton density (1)
- Psychometric evaluation (1)
- Psychometrics (1)
- Quality of care (1)
- Quantitative MRI (1)
- Questionnaires (1)
- REMS (1)
- RNA binding proteins (1)
- RNA extraction (1)
- RNA isolation (1)
- RNAi (1)
- RTS (1)
- RUCAM (1)
- Radiotherapy (1)
- Rare Diseases (1)
- Re-injury (1)
- Reaction time (1)
- Reactive oxygen species (1)
- Real-world evidence (1)
- Recurrence (1)
- Red blood cell transfusion (1)
- Refractory ALL (1)
- Regenerative medicine (1)
- Regression analysis (1)
- Regulatory T cells (1)
- Rehabilitation (1)
- Relapsed ALL (1)
- Relaxometry (1)
- Renal system (1)
- Reproducibility (1)
- Research trends (1)
- Retina (1)
- Retro-IDEAL (1)
- Return to play (1)
- Return to sports (1)
- Rhabdomyosarcoma (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- Rho/Rho-kinase (1)
- Ribosomes (1)
- Risk assessment (1)
- Risk prediction (1)
- Roe deer (1)
- Roughness (1)
- Roussel Uclaf Causality Assessment Method (1)
- Roussel Uclaf Causality Assessment Method (RUCAM) (1)
- S1P (1)
- S1PR1 (1)
- SCA34 (1)
- SCA38 (1)
- SHH (1)
- SILAC (1)
- ST2L (1)
- STAT3 (1)
- SUMO1-3 (1)
- SUMOylation (1)
- SUV (1)
- SW480 cells (1)
- SWATH (1)
- Saccades (1)
- Saccadometry (1)
- Safety (1)
- Salivary gland diseases (1)
- Salvage therapy (1)
- Sarcopenia (1)
- Scanner models (1)
- Scedosporium spp. (1)
- Screening (1)
- Screening guidelines (1)
- Secondary prevention (1)
- Seizure (1)
- Sensory perception (1)
- Sensory systems (1)
- Sequence motif analysis (1)
- Serine proteases (1)
- Serotype 3 (1)
- Severe bacterial infection (1)
- Sex differences (1)
- Signal transduction (1)
- Single-cell RNA-sequencing (1)
- Small RNA analysis (1)
- Smooth muscle cells (1)
- Social epidemiology (1)
- Social health determinants (1)
- Social participation (1)
- Somatization (1)
- Specimen preparation and treatment (1)
- Speech signal processing (1)
- Splanchnic Hemodynamics (1)
- Staphylococcus aureus (1)
- Steatosis (1)
- Stem cell (1)
- Stem cells (1)
- Stenosis (1)
- Sterblichkeit (1)
- Steroid (1)
- Streptococcus pneumoniae (1)
- Stress (1)
- Stress and resilience (1)
- Striatum (1)
- Stromal cell (1)
- Structured reporting (1)
- Subarachnoid hemorrhage (1)
- Subcutaneous (1)
- Surface (1)
- Surgical education (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic reviews (1)
- Systemic lupus erythematosus (1)
- Systems biology (1)
- Systems medicine (1)
- T cell (1)
- T cell receptors (1)
- TBK1 (1)
- TCR signaling cascade (1)
- TEER (1)
- TF-complexes (1)
- TGF-β1 (1)
- TILs (1)
- TIMP2 (1)
- TKI (1)
- TMEM126B (1)
- TMS (1)
- TMT (1)
- TP53-induced glycolysis and apoptosis regulator (1)
- TRIM25 (1)
- Tacrolimus (1)
- Target identification (1)
- Targeted therapies (1)
- Taxane (1)
- Tea (1)
- Telomere length (1)
- Telomeres (1)
- Texture analysis (1)
- Theft (1)
- Therapy (1)
- Therapy response (1)
- Thoracic trauma (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Thromboxane (1)
- Thymocytes (1)
- Thymus (1)
- Tick (1)
- Time in therapeutic range (TTR) (1)
- Time to treatment failure (1)
- Tissue microarray (TMA) (1)
- Tools and ressources (1)
- Total hip replacement (1)
- Toxicity (1)
- Transcription Factors (1)
- Transcriptional control (1)
- Transgender (1)
- Translation initiation (1)
- Translational (1)
- Translational research (1)
- Trees (1)
- Treg cell (1)
- Trimeric autotransporter adhesins (1)
- Trk (1)
- TrkC (1)
- Trousseau’s syndrome (1)
- Trueness (1)
- Tularemia (1)
- Tumor heterogeneity (1)
- Tumour immunology (1)
- U-87MG (1)
- Ulcerative colitis (1)
- Ultrasonography (1)
- Ultrasound (1)
- Umbilical cord (1)
- Unilateral hip osteoarthritis (1)
- United States (1)
- Uveal melanoma (1)
- VARGADO (1)
- VDR (1)
- VEGFA (1)
- VGAT-ChR2 (1)
- VISTA (1)
- Vaccination (1)
- Vaccine breakthrough (1)
- Vacuoles (1)
- Validation (1)
- Vascular disease (1)
- Vasculogenesis (1)
- Veins (1)
- Video-oculography (1)
- Viral load (1)
- Virtual implant planning (1)
- Virtual patients (1)
- Virulence (1)
- Visual acuity (1)
- Visual impairments (1)
- Visual system (1)
- Vitamin K antagonists (1)
- Vitreous opacity (1)
- Vmem (1)
- Volume overload (1)
- Voriconazole (1)
- WNT (1)
- WT1 (1)
- Westphal-Paradigm (1)
- White blood cells (1)
- WoMo score (1)
- Working memory (1)
- Wound healing (1)
- Zebrafish (1)
- Zika virus (1)
- Zoonosis (1)
- abuse (1)
- accidents (1)
- acid sphingomyelinase (ASMase; Smpd1) (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute decompensation (1)
- acute liver failure (1)
- acute lung injury (1)
- acute lung injury (ALI) (1)
- acute-on-chronic liver failure (1)
- adalimumab (1)
- adeno-associated virus (1)
- adeno‐associated virus (1)
- adherence (1)
- adhesion (1)
- adipocytes (1)
- adiponectin (1)
- adipose tissue (1)
- adipose-derived mesenchymal stem cells (1)
- adipose-derived stem cells (1)
- adolescents (1)
- adoptive cancer immunotherapy (1)
- adrenal insuffciency (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adverse effects (1)
- ageing (1)
- aging (1)
- air flow (1)
- air pollution (1)
- airborne bacteria (1)
- albumin (1)
- alcohol (1)
- alcohol dehydrogenase (ADH) (1)
- alcohol metabolism (1)
- alcoholic liver disease (1)
- alcoholic liver injury (1)
- alloHSCT (1)
- allogeneic stem cell transplantation (1)
- alpha receptor (1)
- alpha-synuclein (1)
- amisulpride (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia (1)
- anal cancer (1)
- anaplastic large cell lymphoma (1)
- angio-immunogenic switch (1)
- animal models (1)
- anti-cancer therapy (1)
- antibodies (1)
- anticonvulsant (1)
- antiepileptic drug (1)
- antifibrotic therapy (1)
- antifungal therapy (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- antiviral drugs (1)
- apigenin (1)
- aromatics (1)
- arthritis (1)
- artificial intelligence (1)
- ascites (1)
- associative memory (1)
- astrocytoma (1)
- ataxia score (1)
- ataxia telangiectasia (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- attention modulation (1)
- attention-deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivitydisorder (1)
- attractiveness (1)
- augmentation (1)
- authentication (1)
- autism spectrum disorder (1)
- autologous stem cell transplantation (1)
- automated patch-clamp (1)
- azaindole (1)
- bacteria (1)
- basic mechanisms (1)
- basonuclin 2 (1)
- beam quality correction factors (1)
- belimumab (1)
- beta‐trace protein (1)
- bevacizumab (1)
- binary search procedure (1)
- bioacoustics (1)
- bioactivity (1)
- biofilm (1)
- biological treatments (1)
- biologics (1)
- biomarkers (1)
- biopsy (1)
- bipolar disorder (1)
- bladder cancer (1)
- bladder dose (1)
- blood flow restriction (1)
- bmal1 (1)
- body mass index (1)
- bone chips (1)
- bone damage (1)
- bone healing (1)
- bone loss (1)
- bone marrow derived mononuclear cells (1)
- bone morphogenetic proteins (BMPs) (1)
- bone regeneration (1)
- bone‐screw (1)
- bone–implant interface (1)
- borrelia (1)
- borrelia mayonii (1)
- brachytherapy (1)
- brain phosphorylome (1)
- brain states (1)
- bronchial allergen provocation (1)
- cadherin (1)
- calcitriol (1)
- callous-unemotional traits (1)
- calprotectin (1)
- calretinin (1)
- calretinin-knock out (1)
- cancer cell metabolism (1)
- cancer patients (1)
- cancer stem cells (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabis (1)
- cap-dependent translation (1)
- capsaicin (1)
- car indoor (1)
- carbapenemases (1)
- carbon oxides (COx) (1)
- cardiac myocytes (1)
- cardiomegaly (1)
- cardiovascular (1)
- cardiovascular management (1)
- case reports (1)
- caspase 8 (1)
- caspase-8 (1)
- catheter removal (1)
- cdk (1)
- cell adhesion (1)
- cell biology (1)
- cell cycle arrest (1)
- cell cycling (1)
- cell death (1)
- cell growth (1)
- cell line (1)
- cell motility (1)
- cell survival mechanisms (1)
- cell therapy (1)
- centrifugation (1)
- ceramide (1)
- ceramide synthase (CERS2/CERS1) (1)
- cerebral radiation necrosis (1)
- cerebrovascular disease (1)
- ceritinib (1)
- cervical cancer (1)
- channelrhodopsin (1)
- characterization (1)
- checkpoint proteins (1)
- chemokine receptors (1)
- chemoradiotherapy (1)
- chemoresistance (1)
- chemotherapy (1)
- chemotherapy resistance (1)
- chest injury (1)
- chest trauma (1)
- child (1)
- childhood abuse (1)
- children (1)
- chimeric antigen receptor (1)
- chronic myeloid leukemia (1)
- chronobiology (1)
- cigarette strength (1)
- cigarettes (1)
- circadian rhythm (1)
- circulating miRNA (1)
- classical conditioning (1)
- classification of bone defects (1)
- clinical immunology (1)
- clinical research (1)
- clinical study (1)
- clinical trial (1)
- cloacae (1)
- clock genes (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- cochlear implant (1)
- cognitive deficits (1)
- cognitive functions (1)
- collagen (1)
- collagen I (1)
- collagen degradation marker (1)
- collateral sprouting (1)
- colon carcinoma cells (1)
- colorectal carcinoma (1)
- combination treatment (1)
- common variant (1)
- complex I (1)
- complex I deficiency (1)
- compliance (1)
- computational models (1)
- computational neuroscience (1)
- computational techniques (1)
- computational virology (1)
- concordance (1)
- conduct disorder (1)
- connective tissue graft (1)
- consensus paper (1)
- convolution neural network (1)
- coordination (1)
- copeptin (1)
- cornea donor (1)
- coronary artery bypass graft surgery (1)
- cortical malformation (1)
- cortical thickness (1)
- cortisol (1)
- cost-effective (1)
- courting behavior (1)
- critical size defect (1)
- critically ill patients (1)
- cross-sectional study (1)
- cryopreservation (1)
- cyclin D1 (1)
- cyclins (1)
- cyclosporine (1)
- cystatin C (1)
- cystic fibrosis (1)
- cytochrome P450 2E1 (1)
- cytokine, angiogenesis (1)
- cytotoxic T cells (1)
- death (1)
- death receptor (1)
- deep neural network (1)
- defect configuration (1)
- delayed wound healing (1)
- dental implants (1)
- depression (1)
- depressive symptoms (1)
- desmoplastic small round cell tumor (1)
- detoxification (1)
- diabetic neuropathy (1)
- diffusion tensor imaging (1)
- diffusion tensor imaging (DTI) (1)
- dimethylfumarate (1)
- direct-acting antivirals (DAAs) (1)
- directed disulfide bond formation (1)
- discoidin domain-containing receptor (1)
- discomfort/pain (1)
- disease-free survival (1)
- dissemination (1)
- distal pronephric outlet obstruction (1)
- distress (1)
- docetaxel (1)
- dopamine (1)
- dosimetry (1)
- double inversion recovery (DIR) (1)
- doxorubicin (1)
- drilling tool design (1)
- drug induced liver injury (1)
- drug metabolism and distribution (1)
- drug release (1)
- drug resistance (1)
- drug targets (1)
- drug therapy (1)
- drug-induced liver injury (1)
- drug-induced liver injury (DILI) (1)
- dual task (1)
- dynamic 18F-FDG PET/CT (1)
- early continence (1)
- early loss (1)
- early tumor stages (1)
- economy (1)
- edema (1)
- ejection fraction (EF) (1)
- elderly patients (1)
- electrical stimulation (1)
- electrocardiography (1)
- electron transport chain (1)
- eltrombopag (1)
- emergency care (1)
- emergent self-organizing maps (1)
- emotional information processing (1)
- empowerment (1)
- endometriosis (1)
- endophytes (1)
- endoplasmic reticulum (1)
- endothelial cell (1)
- endothelial cells (1)
- endothelial to mesenchymal transition (1)
- endotoxins (1)
- entorhinal cortex lesion (1)
- envelope technique (1)
- eosinophil cationic protein (1)
- eosinophils (1)
- epigenetic (1)
- epigenetics (1)
- epigenome (1)
- euthymic (1)
- evaluation (1)
- evaluation practice (1)
- everolimus (1)
- evoked response (1)
- evolution (1)
- ex vivo expansion (1)
- excess fluid volume (1)
- executive function (1)
- exercise training (1)
- exosomes (1)
- expression studies (1)
- extracellular vesicles (1)
- eye tracking (1)
- face-name association task (1)
- factor H (1)
- factor IX (1)
- factor VIII (1)
- fat (1)
- fatty acid elongase (Elovl1/4/5) (1)
- fatty acids (1)
- feedback (1)
- femoral artery ligation (1)
- fibroblasts (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fidaxomicin (1)
- fitness (1)
- fixed partial dentures (1)
- fizička aktivnost; (1)
- flavivirus entry factor (1)
- flow cytometry (1)
- fluorescent dye (1)
- focal adhesion (1)
- focal cortical dysplasia (FCD) (1)
- fresh frozen plasma (1)
- full-contour crown restorations (1)
- functional connectivity (1)
- functional genetics (1)
- fungal pathogens (1)
- fungi (1)
- fusion (1)
- gRNA library (1)
- gadolinium‐based contrast agent (1)
- gel spacer injection (1)
- gender (1)
- gender dysphoria (1)
- gender-affirming hormone therapy (1)
- gene expression (1)
- gene expression analysis (1)
- gene regulation (1)
- gene signature (1)
- gene therapy (1)
- genetics (1)
- genetics and genomics (1)
- gene×environment interactions (1)
- genome-wide (1)
- glecaprevir (1)
- glial activation (1)
- glioblastoma (GBM) (1)
- global diversity (1)
- glutamate (1)
- glutamine (1)
- gossypol (1)
- graft-versus host (1)
- granulocytecolony stimulating factor (1)
- granuloma (1)
- gray‐white matter blurring (1)
- growth (1)
- growth hormone (1)
- growth inhibition (1)
- gut microbiota (1)
- haemophilia (1)
- head and neck cancer (1)
- head-to-head (1)
- health apps (1)
- health‐related quality of life (1)
- heart (1)
- heart rate (1)
- heat (1)
- hematopoiesis (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatic osteodystrophy (1)
- hepatic phenotype (1)
- hepatic steatosis (1)
- hepatitis B (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- herb induced liver injury (1)
- hereditary angioedema (1)
- high molecular weight plasticizer (1)
- high-dimensional data sets (1)
- high-dose-rate interstitial brachytherapy (1)
- high-energy photon and proton radiation (1)
- hippocampus (1)
- histone deacetylases (HDACs) (1)
- hospital exemption (1)
- host cell interaction (1)
- host cell response (1)
- host immune response (1)
- host-directed therapies (1)
- hostpathogen interaction (1)
- human Natural Killer cell (1)
- human antigen R (HuR) (1)
- human biology and medicine (1)
- human cytomegalovirus (1)
- human immunodeficiency virus (1)
- human skin graft (1)
- humectant agents (1)
- hygienic hand disinfection (1)
- hygienische Händedesinfektion (1)
- hypertension and anti-hypertensive treatment (1)
- hypoparathyroidism (1)
- hypoxia-inducible factor (1)
- idiopathic dystonia (1)
- idiopathic pulmonary fibrosis (1)
- idiosyncratic DILI (1)
- ifenprodil (1)
- illness experiences (1)
- image analysis (1)
- immune deficiency (1)
- immune dysregulation (1)
- immune landscape (1)
- immune responses (1)
- immune system (1)
- immune-checkpoint inhibition (1)
- immunity (1)
- immunoglobulin superfamily (1)
- immunological research (1)
- immunology and infectious diseases (1)
- immunosuppressive agent (1)
- immunosuppressive drug (1)
- implant movement (1)
- implant stability (1)
- in silico simulation (1)
- in vivo micro‐CT (1)
- indication (1)
- indomethacin (1)
- induced membrane (1)
- infiltration (1)
- inflammatory bowel disease (1)
- information transfer (1)
- inhibitory interneurons (1)
- insect herbivory (1)
- insertion (1)
- insula (1)
- integrated stress response (1)
- intensive care unit (1)
- interferon gamma (1)
- internal ribosomal entry site (IRES) (1)
- interstitial lung disease (1)
- intestinal barrier (1)
- intrinsic DILI (1)
- intrinsic apoptosis (1)
- invasive fungal disease (1)
- ionotropic glutamate receptors (1)
- iron chelation (1)
- iron chelator (1)
- iron chelators (1)
- iron deficiency (1)
- iron homeostasis (1)
- iron metabolism (1)
- irradiation (1)
- isogenic (1)
- ixekizumab (1)
- junctional adhesion molecule (1)
- juvenile myoclonic epilepsy (1)
- kidney transplantation (1)
- kinesin (1)
- lapatinib (1)
- latent tuberculosis infection (1)
- left ventricular function (1)
- legal gender reassignment (1)
- leukocytes (1)
- leukodystrophy (1)
- lifelong learning (1)
- light transmission aggregometry (1)
- liminality (1)
- linoleic acid metabolites (1)
- lipid mediator (1)
- lipid metabolism (1)
- lipids (1)
- lipids inflammatory pain (1)
- lipocalin-2 (1)
- lipopolyplex (1)
- lipopolysaccharide (1)
- lipoxygenase (1)
- liquid-PRF (1)
- liver (1)
- liver adaption (1)
- liver cancer (1)
- liver cell lines (1)
- liver diseases (1)
- liver fibrosis (1)
- liver injury (1)
- liver metabolism (1)
- local control (1)
- long-term distress (1)
- longitudinal relaxation time T1 (1)
- low speed centrifugation concept (1)
- low-back pain (1)
- low-cost medication (1)
- lower urinary tract obstruction (1)
- luteolin (1)
- lyme disease (1)
- lymphangiogenesis (1)
- mGluR3 (1)
- mGluR5 (1)
- mRNA active cancer immunotherapy (1)
- mRNA decay (1)
- mRNA stability (1)
- mTOR inhibition (1)
- mTORC1 (1)
- machine learning (1)
- machine-learning (1)
- maintenance therapy (1)
- major adverse cardiac events (1)
- major depressive disorder (1)
- malignant glioma (1)
- mammary cancer (1)
- mammary carcinoma (1)
- marathon (1)
- maraton (1)
- mass spectrometry (1)
- massive weight loss (1)
- massively parallel multigrid solvers (1)
- mathematical models of viral RNA cycle (1)
- matrix metalloproteinase (1)
- mechanistic target of rapamycin (mTOR) (1)
- medial thigh lift (1)
- medical error (1)
- medulloblastoma resection (1)
- memantine (1)
- memory (1)
- meningioma (1)
- merkel cell carcinoma (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- metabolites (1)
- metastasis (1)
- metastates (1)
- metformin (1)
- methylation profiling (1)
- miR (1)
- miR-143-3p (1)
- miR-181 (1)
- miR-375 (1)
- mice (1)
- microbiome (1)
- microdosing (1)
- microglia (1)
- microsomal ethanol-oxidizing system (MEOS) (1)
- microtubular cytoskeleton (1)
- microtubule disruptors (1)
- mild cognitive impairment (1)
- mitochondrial bioenergetics and glycolysis (1)
- mitochondrial disease (1)
- mitophagy (1)
- mobile phone apps (1)
- mobile tongue cancer (1)
- modeling (1)
- molecular diagnosis (1)
- molecular marker (1)
- montelukast (1)
- motility (1)
- mouse (1)
- mouse model (1)
- movement disorders (1)
- mpMRI (1)
- mtor (1)
- mucosal inflammation (1)
- mucositis (1)
- multidisciplinary pain treatment (1)
- multimorbidity (1)
- multiplex immunofluorescence (1)
- musician (1)
- mutations (1)
- mycophenolate mofetil [MMF] (1)
- myeloid cells (1)
- myocardial infarction (1)
- myocardial injury (1)
- myocardium (1)
- myogenic tone (1)
- myogenic vasoconstriction (1)
- myositis (1)
- nadp (1)
- nanoparticles (1)
- natural killer cells (1)
- nematophin (1)
- neoplasms (1)
- nerve-sparing (1)
- network analysis (1)
- network neuroscience (1)
- neural network (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurodevelopmental disorders (1)
- neuronal silencing (1)
- neurons (1)
- neuropathic pain (1)
- neuropsychological impairment (1)
- neurotrophins (1)
- neutral ceramidase (Asah2) (1)
- neutral sphingomyelinase (Smpd3) (1)
- new miRNA functions (1)
- nintedanib (1)
- nitrogen oxides (NOx) (1)
- nocardia (1)
- nocardiosis (1)
- nodular sclerosis (1)
- non-classical adhesion molecule (1)
- non-invasive fibrosis assessment (1)
- non-sensory bias (1)
- non-small-cell lung cancer (1)
- noradrenaline (1)
- norepinephrine (1)
- nutrient deprivation (1)
- observational cohort study (1)
- oksidacioni stres (1)
- older patients (1)
- olivo-ponto-cerebellar atrophy (OPCA) (1)
- oncogene (1)
- oncolytic virotherapy (1)
- optogenetics (1)
- organ dysfunction (1)
- organ failure (1)
- organisation of health services (1)
- organophosphate flame retardants (OFR) (1)
- orthodontic mini‐implant (1)
- oscillator (1)
- osteoarthritis (1)
- osteogenesis (1)
- osteopenia (1)
- osteotomy (1)
- outcome (1)
- overall survival (1)
- overweight (1)
- oxidative stress (1)
- p14 (1)
- p62 (1)
- p75 (1)
- pack-years (PY) (1)
- pain (1)
- pain management (1)
- pain target (1)
- palatal tremor (1)
- particulate matter (PM) (1)
- passive reading paradigm (1)
- patent (1)
- patient (1)
- patient and public involvement (1)
- patient blood management (1)
- patient perspective (1)
- patient preference (1)
- patient safety (1)
- patients' experience (1)
- patient‐centred outcomes (1)
- pazopanib (1)
- pediatric patients (1)
- pedicle screws (1)
- peficitinib (1)
- perforant path transection (1)
- performance evaluation (1)
- performance-based funding allocation (1)
- perio-prosthetic joint infection (1)
- periodontal probing, (1)
- periodontitis (1)
- perirenal (1)
- peri‐implant lesions (1)
- peri‐implant probing (1)
- peri‐implantitis (1)
- pharmaco-fMRI (1)
- pharmacodynamics (1)
- pharmacogenetics (1)
- pharmacoresistance (1)
- phase 3 study (1)
- phosphatases (1)
- phylogenetic analysis (1)
- physical activity (1)
- pibrentasvir (1)
- pitch perception (1)
- placement (1)
- plant growth (1)
- plant resistance (1)
- plant-insect interactions (1)
- plasmid (1)
- plastic (1)
- plasticity (1)
- platelet aggregation (1)
- platelet lysate (1)
- platelet rich plasma (1)
- platelet-rich fibrin (1)
- platelets (1)
- platform switching (1)
- pleuropericarditis (1)
- point shear wave elastography (1)
- polo-like kinase 1 (1)
- polo-like kinase 3 (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polyethylenimine (1)
- polyomavirus (MCPyV) (1)
- polypharmacology (1)
- population dynamics (1)
- post-translational modifications (PTMs) (1)
- posterior fossa masses (1)
- postmortem blood samples (1)
- posttraumatic stress disorder (1)
- post‐traumatic stress disorder (1)
- power dynamics (1)
- pranlukast (1)
- pre-clinical models (1)
- preeclampsia (1)
- prefrontal cortex (1)
- preoperative anaemia management (1)
- pressure cycling technology (1)
- pressure ulcer treatment (1)
- preterm birth (1)
- primary cilium (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- progestin (1)
- prognosis (1)
- progressive myoclonus epilepsy (1)
- pronephric development (1)
- prophylaxis (1)
- prospective studies (1)
- protein tagging (1)
- proto-oncogene proteins c-akt (1)
- proton density (1)
- proton pump inhibitors (1)
- psoriatic arthritis (1)
- psychological distress (1)
- psychophysiology (1)
- psychosocial stress (1)
- public health (1)
- pulmonary nocardiosis (1)
- pulse labeling (1)
- pulse-spreading harmonic complex (1)
- pupil dilation (1)
- pupillary reactivity (1)
- qualitative research (1)
- quality assurance (1)
- quantitative T1 mapping (1)
- quantitative T1‐difference maps (1)
- radiation therapy (1)
- radioimmunotherpay (1)
- radioresponse (1)
- radixin (1)
- randomized (1)
- rare variant (1)
- re-emerging virus (1)
- re-osseointegration (1)
- reactivation (1)
- reactive oxygen species (ROS) (1)
- reaktivne vrste kiseonika (1)
- real-world data (1)
- realistic geometries (1)
- recertification (1)
- recommendations (1)
- recurrent laryngeal nerve palsy (1)
- refractory aGvHD (1)
- regeneration (1)
- registry for primary immunodeficiency (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- relaxometry (1)
- remote monitoring (1)
- removal (1)
- renal cell cancer (1)
- renin-angiotensin system (1)
- reorganization (1)
- repeat DMEK (1)
- reservoir computing (1)
- resistance (1)
- resistance-associated substitutions (RAS) (1)
- resting-state fMRI (1)
- resting‐state (1)
- retrospective (1)
- revalidation (1)
- revision surgery (1)
- rhabdomyosarcoma (1)
- rhabdomyosarcomas (1)
- rheumatoid arthritis (1)
- ribavirin (1)
- right ventricular function (1)
- risk factor progression (1)
- risk genes (1)
- risk management (1)
- root coverage (1)
- rosetting T cells (1)
- rub-in technique (1)
- running wheel (1)
- sRNA (1)
- sRNA tool (1)
- safety (1)
- scaffold size (1)
- schizophrenia (1)
- schizophrenia spectrum (1)
- sclerostin (1)
- scoping review (1)
- screening test (1)
- screw augmentation (1)
- screw loosening (1)
- second-hand smoke (1)
- secretion (1)
- seed germination (1)
- segmentation (1)
- seizure (1)
- selectin (1)
- sensorimotor exercise training (1)
- sensory neuropathy (1)
- sensory processing (1)
- serine palmitoyltransferase 2 (Sptlc2) (1)
- serologic screening (1)
- serositis (1)
- serum albumin deficiency (1)
- severe vitamin D deficiency (1)
- sex differences (1)
- sexually transmitted diseases (1)
- sexually transmitted infection (1)
- sham (1)
- shortening of treatment (1)
- shunt (1)
- siRNA analysis (1)
- siRNA delivery (1)
- siRNA quantification (1)
- siRNA/RNAi (1)
- signature (1)
- silicone device (1)
- simulation (1)
- simulation training (1)
- single-sided deafness (1)
- sinus rhythm (1)
- six-step technique (1)
- smoking (1)
- sofosbuvir (1)
- soft tissue sarcoma (1)
- soft tissue sarcoma (STS) (1)
- soluble epoxide hydrolase (1)
- somatic mutations (1)
- sonic hedgehog signaling (1)
- sound-induced flash illusion (1)
- spatial specificity (1)
- spectroscopy (1)
- sphingolipid (1)
- spider toxin (1)
- spiking neural networks (1)
- spinal fusion (1)
- spirochete (1)
- spirochetes (1)
- starvation (1)
- stem cell transplantation (1)
- steroid-resistant aGvHD (1)
- stimulation (1)
- stopping rule (1)
- stratification (1)
- strength training (1)
- stress response (1)
- stroke (1)
- structural covariance (1)
- subcutaneous fat (1)
- subjunctivity (1)
- success rate (1)
- sulfasalazine (1)
- suplementacija (1)
- supplementation (1)
- support vector machines (1)
- surveillance (1)
- survival (1)
- survival rate (1)
- synaptic signaling (1)
- synovial fibroblast (1)
- systemic inflammation (1)
- t-distributed stochastic neighbor embedding (1)
- tDCS (1)
- tacrolimus (1)
- target variability (1)
- telemedicine (1)
- telmisartan (1)
- temozolomide (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- thighplasty (1)
- thrombocyte dysfunction (1)
- thrombocyte function (1)
- thrombolysis (tPA) (1)
- thrombopietin receptor agonist (1)
- thrombospondin-4 (1)
- thymus (1)
- thyroid resection (1)
- tissue Doppler imaging (1)
- tissue engineering (1)
- tolerance (1)
- tongue edema (1)
- topographic maps (1)
- total joint arthroplasty (TJA) (1)
- trafficking (1)
- transcriptional profiling (1)
- transcriptome (1)
- transdifferentiation (1)
- transforming growth factor beta (1)
- transforming growth factor beta (TGF-β) (1)
- transient elastography (1)
- transient receptor potential channels (1)
- translation (1)
- transmission and vector control (1)
- transsexualism (1)
- trastuzumab (1)
- trophoblastic cell lines (1)
- trophoblasts (1)
- troponin (1)
- tumor (1)
- tumor growth (1)
- tumor immune evasion (1)
- tumor microenviroment (1)
- tumor progression (1)
- tumor proliferation (1)
- tumor‐associated macrophages (1)
- two-tissue compartment model (1)
- tyrosine kinase inhibitor (1)
- ulcerative colitis (1)
- uncertainty (1)
- unfolded protein response (1)
- ustekinumab (1)
- uterine cervical cancer (1)
- vaccine (1)
- valproic acid (1)
- vancomycin (1)
- vascular complications (1)
- vascular disease (1)
- vascular dysfunction and inflammation (1)
- vascular smooth muscle (1)
- velpatasvir (1)
- ventral tegmental area (1)
- vesicovaginal septum (1)
- viability (1)
- viral dynamics (1)
- viral gene transfer (1)
- virulence (1)
- vitamin D supplementation (1)
- vitamin D target genes (1)
- vitamin Dmetabolism (1)
- voice (1)
- volatile organic compounds (VOC) (1)
- voluntary training (1)
- voxilaprevir (1)
- within-host viral modeling (1)
- women (1)
- words (1)
- work-life balance (1)
- working conditions (1)
- wound healing (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
- zafirlukast (1)
- zebrafish (1)
- zirconia (1)
- Überwachung (1)
- β-catenin (1)
- β-lactamases (1)
- γδT cell (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- flow cytometry (1)
Institute
- Medizin (500) (remove)
Background: Remodeling of extracellular matrix through collagen degradation is a crucial step in the metastatic cascade. The aim of this study was to evaluate the potential clinical relevance of the serum collagen degradation markers (CDM) C3M and C4M during neoadjuvant chemotherapy for breast cancer.
Methods: Patients from the GeparQuinto phase 3 trial with untreated HER2-positive operable or locally advanced breast cancer were enrolled between 7 November 2007, and 9 July 2010, and randomly assigned to receive neoadjuvant treatment with EC/docetaxel with either trastuzumab or lapatinib. Blood samples were collected at baseline, after four cycles of chemotherapy and at surgery. Cutoff values were determined using validated cutoff finder software (C3M: Low ≤9.00 ng/mL, high >9.00 ng/mL, C4M: Low ≤40.91 ng/mL, high >40.91 ng/mL).
Results: 157 patients were included in this analysis. At baseline, 11.7% and 14.8% of patients had high C3M and C4M serum levels, respectively. No correlation was observed between CDM and classical clinical-pathological factors. Patients with high levels of CDM were significantly more likely to achieve a pathological complete response (pCR, defined as ypT0 ypN0) than patients with low levels (C3M: 66.7% vs. 25.7%, p = 0.002; C4M: 52.7% vs. 26.6%, p = 0.031). Median levels of both markers were lower at the time of surgery than at baseline. In the multivariate analysis including clinical-pathological factors and C3M levels at baseline and changes in C3M levels between baseline and after four cycles of therapy, only C3M levels at baseline (p = 0.035, OR 4.469, 95%-CI 1.115–17.919) independently predicted pCR. In a similar model including clinical-pathological factors and C4M, only C4M levels at baseline (p = 0.028, OR 6.203, 95%-CI 1.220–31.546) and tumor size (p = 0.035, OR 4.900, 95%-CI 1.122–21.393) were independent predictors of pCR. High C3M levels at baseline did not correlate with survival in the entire cohort but were associated with worse disease-free survival (DFS; p = 0.029, 5-year DFS 40.0% vs. 74.9%) and overall survival (OS; p = 0.020, 5-year OS 60.0% vs. 88.3%) in the subgroup of patients randomized to lapatinib. In the trastuzumab arm, C3M did not correlate with survival. In the entire patient cohort, high levels of C4M at baseline were significantly associated with shorter DFS (p = 0.001, 5-year DFS 53.1% vs. 81.6%) but not with OS. When treatment arms were considered separately, the association with DFS was still significant (p = 0.014, 5-year DFS 44.4% vs. 77.0% in the lapatinib arm; p = 0.023, 5-year DFS 62.5% vs. 86.2% in the trastuzumab arm).
Conclusions: Collagen degradation markers are associated with response to neoadjuvant therapy and seem to play a role in breast cancer.
Background: The nonmotor symptom spectrum of Parkinson’s disease (PD) includes progressive cognitive decline mainly in late stages of the disease. The aim of this study was to map the patterns of altered structural connectivity of patients with PD with different cognitive profiles ranging from cognitively unimpaired to PD-associated dementia.
Methods: Diffusion tensor imaging and neuropsychological data from the observational multicentre LANDSCAPE study were analyzed. A total of 134 patients with PD with normal cognitive function (56 PD-N), mild cognitive impairment (67 PD-MCI), and dementia (11 PD-D) as well as 72 healthy controls were subjected to whole-brain-based fractional anisotropy mapping and covariance analysis with cognitive performance measures.
Results: Structural data indicated subtle changes in the corpus callosum and thalamic radiation in PD-N, whereas severe white matter impairment was observed in both PD-MCI and PD-D patients including anterior and inferior fronto-occipital, uncinate, insular cortices, superior longitudinal fasciculi, corona radiata, and the body of the corpus callosum. These regional alterations were demonstrated for PD-MCI and were more pronounced in PD-D. The pattern of involved regions was significantly correlated with the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) total score.
Conclusions: The findings in PD-N suggest impaired cross-hemispherical white matter connectivity that can apparently be compensated for. More pronounced involvement of the corpus callosum as demonstrated for PD-MCI together with affection of fronto-parieto-temporal structural connectivity seems to lead to gradual disruption of cognition-related cortico-cortical networks and to be associated with the onset of overt cognitive deficits. The increase of regional white matter damage appears to be associated with the development of PD-associated dementia.
Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases
(2019)
Background: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40% is due to more effective treatments of extracerebral sites with improved prognosis and increasing use of MRI in diagnostics. A frequently administered, potent chemotherapeutic group of drugs for BC treatment are taxanes usually used in the adjuvant and metastatic setting, which, however, have been suspected to be associated with a higher incidence of BM. The aim of our study was to experimentally analyze the impact of the taxane docetaxel (DTX) on brain metastasis formation, and to elucidate the underlying molecular mechanism.
Methods: A monocentric patient cohort was analyzed to determine the association of taxane treatment and BM formation. To identify the specific impact of DTX, a murine brain metastatic model upon intracardial injection of breast cancer cells was conducted. To approach the functional mechanism, dynamic contrast-enhanced MRI and electron microscopy of mice as well as in-vitro transendothelial electrical resistance (TEER) and tracer permeability assays using brain endothelial cells (EC) were carried out. PCR-based, immunohistochemical and immunoblotting analyses with additional RNA sequencing of murine and human ECs were performed to explore the molecular mechanisms by DTX treatment.
Results: Taxane treatment was associated with an increased rate of BM formation in the patient cohort and the murine metastatic model. Functional studies did not show unequivocal alterations of blood-brain barrier properties upon DTX treatment in-vivo, but in-vitro assays revealed a temporary DTX-related barrier disruption. We found disturbance of tubulin structure and upregulation of tight junction marker claudin-5 in ECs. Furthermore, upregulation of several members of the tubulin family and downregulation of tetraspanin-2 in both, murine and human ECs, was induced.
Conclusion: In summary, a higher incidence of BM was associated with prior taxane treatment in both a patient cohort and a murine mouse model. We could identify tubulin family members and tetraspanin-2 as potential contributors for the destabilization of the blood-brain barrier. Further analyses are needed to decipher the exact role of those alterations on tumor metastatic processes in the brain.
Background & Aims: Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non‐adherence can potentially result in treatment failure and the emergence of resistant viral variants. This analysis assessed factors associated with non‐adherence to glecaprevir/pibrentasvir (G/P) therapy and the impact of non‐adherence on sustained virological response at post‐treatment week 12 (SVR12) rates in HCV genotype (GT) 1‐6‐infected patients.
Methods: Adherence was calculated by pill counts at study visits during treatment, and defined as having a lowest treatment adherence of ≥80% and ≤120% at each study visit. Exploratory logistic regression modelling assessed predictors of non‐adherence to G/P therapy. SVR12 rates by treatment adherence were assessed in the intent‐to‐treat (ITT) population and modified ITT (mITT) population, which excludes non‐virological failures.
Results: Overall, 97% (2024/2091) of patients were adherent to G/P therapy at all consecutive study visits. Alcohol use was the only baseline characteristic independently associated with non‐adherence to G/P therapy (OR: 2.38; 95% CI: 1.13‐5.01; P = .022). In the mITT population, overall SVR12 rates were high both in patients who were adherent to G/P therapy and those who were not (99% [1983/2008] and 95% [58/61] respectively; P = .047). Corresponding SVR12 rates in the ITT population were 98% (1983/2024) and 87% (58/67) respectively.
Conclusions: Most patients adhered to G/P therapy. SVR12 rates were high both in patients who were adherent to G/P treatment and those who were not. Patient education on treatment adherence should remain an important part of HCV treatment.
Clinical trials registration: NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, NCT02243293, NCT02446717.
Background: Disease progression and delayed neurological complications are common after aneurysmal subarachnoid hemorrhage (aSAH). We explored the potential of quantitative blood-brain barrier (BBB) imaging to predict disease progression and neurological outcome.
Methods: Data were collected as part of the Co-Operative Studies of Brain Injury Depolarizations (COSBID). We analyzed retrospectively, blinded and semi-automatically magnetic resonance images from 124 aSAH patients scanned at 4 time points (24–48 h, 6–8 days, 12–15 days and 6–12 months) after the initial hemorrhage. Volume of brain with apparent pathology and/or BBB dysfunction (BBBD), subarachnoid space and lateral ventricles were measured. Neurological status on admission was assessed using the World Federation of Neurosurgical Societies and Rosen-Macdonald scores. Outcome at ≥6 months was assessed using the extended Glasgow outcome scale and disease course (progressive or non-progressive based on imaging-detected loss of normal brain tissue in consecutive scans). Logistic regression was used to define biomarkers that best predict outcomes. Receiver operating characteristic analysis was performed to assess accuracy of outcome prediction models.
Findings: In the present cohort, 63% of patients had progressive and 37% non-progressive disease course. Progressive course was associated with worse outcome at ≥6 months (sensitivity of 98% and specificity of 97%). Brain volume with BBBD was significantly larger in patients with progressive course already 24–48 h after admission (2.23 (1.23–3.17) folds, median with 95%CI), and persisted at all time points. The highest probability of a BBB-disrupted voxel to become pathological was found at a distance of ≤1 cm from the brain with apparent pathology (0·284 (0·122–0·594), p < 0·001, median with 95%CI). A multivariate logistic regression model revealed power for BBBD in combination with RMS at 24-48 h in predicting outcome (ROC area under the curve = 0·829, p < 0·001).
Interpretation: We suggest that early identification of BBBD may serve as a key predictive biomarker for neurological outcome in aSAH.
Fund: Dr. Dreier was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) (DFG DR 323/5-1 and DFG DR 323/10–1), the Bundesministerium für Bildung und Forschung (BMBF) Center for Stroke Research Berlin 01 EO 0801 and FP7 no 602150 CENTER-TBI.
Dr. Friedman was supported by grants from Israel Science Foundation and Canada Institute for Health Research (CIHR). Dr. Friedman was supported by grants from European Union's Seventh Framework Program (FP7/2007–2013; grant #602102).
Despite advances in the treatment of acute myeloid leukemia (AML), prognosis of AML patients is still dismal and better treatment options are required. B-cell Lymphoma 2 (BCL-2) homology domain 3 (BH3)-mimetics are emerging as a novel class of apoptosis-inducing agents that are currently being tested for the treatment of different hematological malignancies including AML. Particularly, the selective BCL-2 inhibitor ABT-199/Venetoclax is demonstrating clinical responses and has recently been approved in combination for the treatment of AML. Compounds targeting the related protein MCL-1 have recently entered clinical trials, highlighting the urgency to compare the different BH3-mimetics and identify the most promising antiapoptotic target in AML. We performed a side-by-side comparison of different highly selective and potent BH3-mimetics targeting BCL-2 (ABT-199), MCL-1 (S63845) or BCL-xL (A1331852) in a panel of AML cell lines and primary patient cells. Gene knockdown using siRNAs was utilized to investigate the functional relevance of BCL-2 proteins. Western blotting and immunoprecipitations were used to explore the influence of BH3-mimetics on interactions between pro- and antiapoptotic BCL-2 proteins. A1331852 induced apoptosis only in selected cases, indicating that BCL-xL is not a very promising therapeutic target in AML. However, S63845 displayed higher potency than ABT-199, with more cell lines and primary cells responding to S63845 than to ABT-199. MCL-1 dependency in AML cells was confirmed by siRNA-mediated knockdown of MCL-1, which was sufficient to induce apoptosis. S63845-induced cell death was accompanied by a displacement of the BH3-only protein BIM as well as BAK, resulting in BAK-dependent apoptosis. In contrast, ABT-199-induced cell death was mediated by BAX rather than BAK, indicating distinct non-redundant molecular functions of BCL-2 and MCL-1 in AML. Our study reveals that MCL-1 may be a more prevalent therapeutic target than BCL-2 in AML and identifies BIM and BAK as important mediators of S63845-induced apoptosis in AML.
Constitutive Wnt activation upon loss of Adenoma polyposis coli (APC) acts as main driver of colorectal cancer (CRC). Targeting Wnt signaling has proven difficult because the pathway is crucial for homeostasis and stem cell renewal. To distinguish oncogenic from physiological Wnt activity, we have performed transcriptome and proteome profiling in isogenic human colon organoids. Culture in the presence or absence of exogenous ligand allowed us to discriminate receptor-mediated signaling from the effects of CRISPR/Cas9-induced APC loss. We could catalog two nonoverlapping molecular signatures that were stable at distinct levels of stimulation. Newly identified markers for normal stem/progenitor cells and adenomas were validated by immunohistochemistry and flow cytometry. We found that oncogenic Wnt signals are associated with good prognosis in tumors of the consensus molecular subtype 2 (CMS2). In contrast, receptor-mediated signaling was linked to CMS4 tumors and poor prognosis. Together, our data represent a valuable resource for biomarkers that allow more precise stratification of Wnt responses in CRC.
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome.
Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death.
Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend).
Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low.
Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402.
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin–kexin type 9 inhibition in such patients is undetermined.
Objectives: This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease influenced risks of MACEs and death and their modification by alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy.
Methods: Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. All-cause death was a secondary endpoint.
Results: Median follow-up was 2.8 years. Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyvascular disease in 2 beds (coronary and peripheral artery or cerebrovascular), and 149 had polyvascular disease in 3 beds (coronary, peripheral artery, cerebrovascular). With placebo, the incidence of MACEs by respective vascular categories was 10.0%, 22.2%, and 39.7%. With alirocumab, the corresponding absolute risk reduction was 1.4% (95% confidence interval [CI]: 0.6% to 2.3%), 1.9% (95% CI: −2.4% to 6.2%), and 13.0% (95% CI: −2.0% to 28.0%). With placebo, the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab was 0.4% (95% CI: −0.1% to 1.0%), 1.3% (95% CI: −1.8% to 4.3%), and 16.2% (95% CI: 5.5% to 26.8%).
Conclusions: In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death. The large absolute reductions in those risks with alirocumab are a potential benefit for these patients. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]: NCT01663402)
Advances in flow cytometry enable the acquisition of large and high-dimensional data sets per patient. Novel computational techniques allow the visualization of structures in these data and, finally, the identification of relevant subgroups. Correct data visualizations and projections from the high-dimensional space to the visualization plane require the correct representation of the structures in the data. This work shows that frequently used techniques are unreliable in this respect. One of the most important methods for data projection in this area is the t-distributed stochastic neighbor embedding (t-SNE). We analyzed its performance on artificial and real biomedical data sets. t-SNE introduced a cluster structure for homogeneously distributed data that did not contain any subgroupstructure. Inotherdatasets,t-SNEoccasionallysuggestedthewrongnumberofsubgroups or projected data points belonging to different subgroups, as if belonging to the same subgroup. As an alternative approach, emergent self-organizing maps (ESOM) were used in combination with U-matrix methods. This approach allowed the correct identification of homogeneous data while in sets containing distance or density-based subgroups structures; the number of subgroups and data point assignments were correctly displayed. The results highlight possible pitfalls in the use of a currently widely applied algorithmic technique for the detection of subgroups in high dimensional cytometric data and suggest a robust alternative.
Liver injuries caused by the use of exogenous compounds such as drugs, herbs, and alcohol are commonly well diagnosed using laboratory tests, toxin analyses, or eventually reactive intermediates generated during metabolic degradation of the respective chemical in the liver and subject to covalent binding by target proteins. Conditions are somewhat different for idiosyncratic drug induced liver injury (DILI), for which metabolic intermediates as diagnostic aids are rarely available. Although the diagnosis of idiosyncratic DILI can well be established using the validated, liver specific, structured, and quantitative RUCAM (Roussel Uclaf Causality Assessment Method), there is an ongoing search for new diagnostic biomarkers that could assist in and also confirm RUCAM-based DILI diagnoses. With respect to idiosyncratic DILI and following previous regulatory letters of recommendations, selected biomarkers reached the clinical focus, including microRNA-122, microRNA-192, cytokeratin analogues, glutamate dehydrogenase, total HMGB-1 (High Mobility Group Box), and hyperacetylated HMGB-1 proteins. However, the new parameters total HMGB-1, and even more so the acetylated HMGB-1, came under critical scientific fire after misconduct at one of the collaborating partner centers, leading the EMA to recommend no longer the exploratory hyperacetylated HMGB1 isoform biomarkers in clinical studies. The overall promising nature of the recommended biomarkers was considered by EMA as highly dependent on the outstanding results of the now incriminated biomarker hyperacetylated HMGB-1. The EMA therefore correctly decided to officially retract its Letter of Support affecting all biomarkers listed above. New biomarkers are now under heavy scrutiny that will require re-evaluations prior to newly adapted recommendations. With Integrin beta 3 (ITGB3), however, a new diagnostic biomarker may emerge, possibly being drug specific but tested in only 16 patients; due to substantial remaining uncertainties, final recommendations would be premature. In conclusion, most of the currently recommended new biomarkers have lost regulatory support due to scientific misconduct, requiring now innovative approaches and re-evaluation before they can be assimilated into clinical practice.
Background: Glial cells in the central nervous system play a key role in neuroinflammation and subsequent central sensitization to pain. They are therefore involved in the development of persistent pain. One of the main sites of interaction of the immune system with persistent pain has been identified as neuro-immune crosstalk at the glialopioid interface. The present study examined a potential association between the DNA methylation of two key players of glial/opioid intersection and persistent postoperative pain. Methods: In a cohort of 140 women who had undergone breast cancer surgery, and were assigned based on a 3year follow-up to either a persistent or non-persistent pain phenotype, the role of epigenetic regulation of key players in the glial-opioid interface was assessed. The methylation of genes coding for the Toll-like receptor 4 (TLR4) as a major mediator of glial contributions to persistent pain or for the μ-opioid receptor (OPRM1) was analyzed and its association with the pain phenotype was compared with that conferred by global genome-wide DNA methylation assessed via quantification of the methylation in the retrotransposon LINE1. Results: Training of machine learning algorithms indicated that the global DNA methylation provided a similar diagnostic accuracy for persistent pain as previously established non-genetic predictors. However, the diagnosis can be based on a single DNA based marker. By contrast, the methylation of TLR4 or OPRM1 genes could not contribute further to the allocation of the patients to the pain-related phenotype groups. Conclusions: While clearly supporting a predictive utility of epigenetic testing, the present analysis cannot provide support for specific epigenetic modulation of persistent postoperative pain via methylation of two key genes of the glial-opioid interface.
Phlotoxin-1 (PhlTx1) is a peptide previously identified in tarantula venom (Phlogius species) that belongs to the inhibitory cysteine-knot (ICK) toxin family. Like many ICK-based spider toxins, the synthesis of PhlTx1 appears particularly challenging, mostly for obtaining appropriate folding and concomitant suitable disulfide bridge formation. Herein, we describe a procedure for the chemical synthesis and the directed sequential disulfide bridge formation of PhlTx1 that allows for a straightforward production of this challenging peptide. We also performed extensive functional testing of PhlTx1 on 31 ion channel types and identified the voltage-gated sodium (Nav) channel Nav1.7 as the main target of this toxin. Moreover, we compared PhlTx1 activity to 10 other spider toxin activities on an automated patch-clamp system with Chinese Hamster Ovary (CHO) cells expressing human Nav1.7. Performing these analyses in reproducible conditions allowed for classification according to the potency of the best natural Nav1.7 peptide blockers. Finally, subsequent in vivo testing revealed that intrathecal injection of PhlTx1 reduces the response of mice to formalin in both the acute pain and inflammation phase without signs of neurotoxicity. PhlTx1 is thus an interesting toxin to investigate Nav1.7 involvement in cellular excitability and pain
Background: In Germany, patients receiving oral anticoagulation (OAC) are often treated by general practitioners (GPs), and large proportions of patients receive vitamin K antagonists (VKAs). The quality of OAC in German GP practices, differences between various practices, and improvement potential through implementation of case management, have not yet been investigated satisfactorily.
Based on results of a cluster-randomized controlled trial, we aimed to assess whether OAC quality can be improved, any variations between practices exist and determine practice- and patient-level factors.
Methods: The PICANT trial (2012–2015) was performed in 52 GP practices in Hesse, Germany. Adult patients with long-term indication for OAC received best practice case management in the intervention group. International normalized ratio (INR) values were recorded from anticoagulation passes. The Rosendaal method was used to calculate Time in Therapeutic Range (TTR) at patient level, and mean pooling to obtain center-specific TTR (cTTR) at practice level. The quality of OAC was assessed by TTR and cTTR. Linear model analyses were used to investigate associations between practice−/ patient-level factors and TTR.
Results: Inclusion of 736 patients (49.6% intervention and 50.4% control patients); 690 (93.8%) received phenprocoumon. Within 24 months, the TTR was 75.1% (SD 17.6) in the intervention versus 74.3% (SD 17.8) in the control group (p = 0.670). The cTTR averaged 75.1% (SD 6.5, range: 60.4 to 86.7%) in the intervention versus 74.3% (SD 7.2, range: 52.7 to 85.7%) in the control group (p = 0.668). At practice level, the TTR was significantly lower in practices with a male physician and certification in quality management. At patient level, the TTR was significantly higher in patients with moderate to high compliance, in men, and in patients that performed self-management. The TTR was significantly lower in patients with certain comorbidities, and who were hospitalized.
Conclusions: The intervention did not effectively improve OAC quality compared to routine care. Quality of INR control was generally good, but considerable variation existed between GP practices. The variability indicates optimization potential in some practices. The demonstrated association between patient-level factors and TTR highlights the importance of considering patient characteristics that may impede achieving high quality therapeutic outcomes.
Trial registration: ISRCTN registry, ISRCTN41847489, registered 27 February 2012.
Background: Understanding the location and cell-type specific binding of Transcription Factors (TFs) is important in the study of gene regulation. Computational prediction of TF binding sites is challenging, because TFs often bind only to short DNA motifs and cell-type specific co-factors may work together with the same TF to determine binding. Here, we consider the problem of learning a general model for the prediction of TF binding using DNase1-seq data and TF motif description in form of position specific energy matrices (PSEMs).
Methods: We use TF ChIP-seq data as a gold-standard for model training and evaluation. Our contribution is a novel ensemble learning approach using random forest classifiers. In the context of the ENCODE-DREAM in vivo TF binding site prediction challenge we consider different learning setups.
Results: Our results indicate that the ensemble learning approach is able to better generalize across tissues and cell-types compared to individual tissue-specific classifiers or a classifier built based upon data aggregated across tissues. Furthermore, we show that incorporating DNase1-seq peaks is essential to reduce the false positive rate of TF binding predictions compared to considering the raw DNase1 signal.
Conclusions: Analysis of important features reveals that the models preferentially select motifs of other TFs that are close interaction partners in existing protein protein-interaction networks. Code generated in the scope of this project is available on GitHub: https://github.com/SchulzLab/TFAnalysis (DOI: 10.5281/zenodo.1409697).
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
COPA syndrome is a newly discovered hereditary immunodeficiency affecting the lung, kidneys, and joints. The mutated gene encodes the α subunit of the coatomer complex I, a protein transporter from the Golgi back to the endoplasmic reticulum. The impaired return of proteins leads to intracellular stress. The syndrome is an autoimmune and autoinflammatory disease that can be grouped among the interferonopathies. The knowledge about COPA syndrome and its treatment is still limited. In this paper, we describe an additional patient, a 15-year-old girl with rheumatoid factor-positive polyarthritis and rheumatoid nodules since the age of 2, who developed interstitial lung disease. The detected mutation c.698G>A was causing the disease. The patient presented with symmetric polyarthritis on wrists, fingers, and hip and ankle joints, with significant functional impairment, and high disease activity. Laboratory parameters demonstrated chronic inflammation, hypergammaglobulinemia, high titre ANA (antinuclear antibodies) and CCP (anti-citrullinated protein) antibodies, and rheumatoid factors. Therapies with various DMARDs (Disease Modifying Anti-Rheumatic Drugs) and biologicals failed. Upon baricitinib application, the clinical activity decreased dramatically with disappearance of joint pain and morning stiffness and significant decrease of joint swelling. A low disease activity was reached after 12 months, with complete disappearance of rheumatoid nodules. In contrast to IL-1 (interleukin-1), IL-6, and TNF (tumor necrosis factor) inhibitors, baricitinib was very successful, probably because baricitinib acts as a JAK-1/2 (janus kinase-1/2) inhibitor in the IFNα/β (inteferone α/β) pathway. A relatively higher dose in children is necessary. COPA syndrome represents a novel disorder of intracellular transport. Reviewing published literature on COPA syndrome, in addition to our patient, there were 31 cases further described.
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
Platelet function (PF) plays a pivotal role in both hemostasis and thrombosis, and manual light transmission aggregometry (LTA) is considered the standard of care for platelet function testing but is an error-prone and time-consuming procedure. We aimed to test the agreement regarding maximum aggregation (MA), velocity (VEL), and lag-phase (LagP) of platelet aggregation of the automated Sysmex CS-2100i analyzer (Siemens, Germany) against the APACT 4004 (Elitech, France) in samples derived from healthy participants and patients with hemostaseologic disorders. In total, 123 patient-derived samples were investigated, including 42 patients with acetylsalicylic acid and/or clopidogrel intake and 20 patients with other hemostaseologic disorders. Both MA and VEL showed good or excellent intermethod correlation. Agreement between the testing methods was only partially achieved, and values were indicative for a systematic bias to lower measurements below a threshold of 50% MA with the CS-2100i compared to the APACT 4004. All patients with impaired PF in the APACT 4004 were successfully identified with the CS-2100i, and reference values for automated LTA are provided. Conclusively, automated LTA with the CS-2100i is a highly standardized and reliable PF testing method and represents a decisive step in the simplification of platelet function testing in clinical routine.
We recently described a positive feedback loop connecting c-MYC, NAMPT, DBC1 and SIRT1 that contributes to unrestricted cancer cell proliferation. Here we determine the relevance of the loop for serrated route intestinal tumorigenesis using genetically well-defined BrafV600E and K-rasG12D mouse models. In both models we show that c-MYC and SIRT1 protein expression increased through progression from hyperplasia to invasive carcinomas and metastases. It correlated with high NAMPT expression and was directly associated to activation of the oncogenic drivers. Assessing functional and molecular consequences of pharmacological interference with factors of the loop, we found that inhibition of NAMPT resulted in apoptosis and reduced clonogenic growth in human BRAF-mutant colorectal cancer cell lines and patient-derived tumoroids. Blocking SIRT1 activity was only effective when combined with a PI3K inhibitor, whereas the latter antagonized the effects of NAMPT inhibition. Interfering with the positive feedback loop was associated with down-regulation of c-MYC and temporary de-repression of TP53, explaining the anti-proliferative and pro-apoptotic effects. In conclusion we show that the c-MYC-NAMPT-DBC1-SIRT1 positive feedback loop contributes to murine serrated tumor progression. Targeting the feedback loop exerted a unique, dual therapeutic effect of oncoprotein inhibition and tumor suppressor activation. It may therefore represent a promissing target for serrated colorectal cancer, and presumably for other cancer types with deregulated c-MYC.